Fairvalue-Calculator Fairvalue-Calculator
EN DE

Atrium Therapeutics, Inc (RNA) Fair Value & Analysis

Healthcare · US · Market cap $217M

Price$12.83
Fair Value$11.80
Upside-8.0%
Quality95/100
Evidence: Low Range $7.79 – $14.75

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Atrium Therapeutics, Inc (RNA) currently trades at $12.83, while our model-based Fair Value estimate is $11.80 — implying the stock looks roughly 8.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Atrium Therapeutics, Inc (RNA) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $11.80 versus a price of $12.83 — about −8% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RNA?
Our 21-model fair value for Atrium Therapeutics, Inc is $11.80 (as of Jun 25, 2026), built from audited fundamentals. The current price is $12.83.
What is the quality score of RNA?
Atrium Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.